Corvus Pharmaceuticals, Inc. (CRVS) Earnings Call Transcript & Summary
May 8, 2025
Earnings Call Speaker Segments
Zack Kubow
executiveThanks a lot, Operator, and hello to all of you this afternoon. We appreciate you being with us on today's call. A webcast with presentation slides is available for this conference call. We ask that participants join the webcast so they can see the slides. The link to join the webcast is posted on the Investor Relations homepage of the Corvus website. Moving to slide two, I want to remind everybody that remarks made by management today, along with responses to questions, will contain forward-looking statements. Such forward-looking statements rest on estimates and assumptions as of today and carry risks and uncertainties that could lead actual results to differ materially from those expressed or implied by those statements, including the risks and uncertainties described in Corvus' quarterly report on Form 10Q for the quarter ended March 31st, 2025, and other filings the company makes with the SEC from time to time. Except as required by law, the company undertakes no obligation to publicly update or revise any forward-looking statements. Slide three shows the agenda for the call. We'll start with a short overview of the first quarter financial results, then move to a detailed review of the Soquelitinib atopic dermatitis phase I data announced today and being presented at the Society for Investigative Dermatology annual meeting this week. After that, we'll give a broader business update, and then open the call for questions and answers. Joining us from Corvus are Dr. Richard Miller, Chief Executive Officer, Leiv Lea, Chief Financial Officer, Jeff Arcara, Chief Business Officer, and Dr. Suresh Mahabhashyam, Vice President of Clinical Development. With that, I'd like to turn the call over to Leiv Lea. Leiv.
Leiv Lea
executiveThanks, Zack. I'll walk through the main financial points from our first quarter. For R&D spending, we saw $7.5 million in Q1 2025, up from $4.1 million during the same stretch in 2024. That $3.4 million bump came largely from greater clinical trial and manufacturing expenses tied to developing Soquelitinib, plus higher costs related to personnel. Net income for the first quarter of 2025 reached $15.2 million, which included a $0.5 million non-cash loss connected to Angel Pharmaceuticals, our partner in China. On top of that, we booked a $25.1 million non-cash gain during Q1 2025 stemming from the change in fair value of Corvus' warrant liability; that contrasts with a net loss of $5.7 million for the same period in 2024, a figure that included a $0.2 million non-cash gain tied to Angel Pharmaceuticals. Stock compensation expense totaled $1.3 million in the first quarter of 2025, versus $0.7 million for the same period in 2024. At March 31st, 2025, Corvus held cash, cash equivalents, and marketable securities of $44.2 million, compared with $52 million at December 31st, 2024; during May 2025, holders of 8,945,000 common stock warrants exercised every one of their warrants ahead of the June 30th, 2025, expiration date, generating cash proceeds to Corvus of roughly $31.3 million. Richard Miller likewise exercised all 559,000 of his warrants. Every warrant was exercised at $3.50 per share. Given our current plans, we anticipate that our existing cash, together with the warrant proceeds, will fund operations into the fourth quarter of 2026. I'll now hand the call to Richard, who will go over the Soquelitinib phase I data reported today and cover other company progress and updates.
Richard Miller
executiveThanks, Leiv, and hello to everyone this afternoon. We appreciate you taking part in today's update call. It's great to be here with you in San Diego, where the Society for Investigative Dermatology annual meeting — SID — is taking place. Later today, a poster will feature data from our phase I trial of soquelitinib in atopic dermatitis patients, and on Saturday, Dr. Albert Chu of the Department of Dermatology at Stanford University Medical Center will present in an oral session. We see these results as highly encouraging, since every treatment cohort showed a favorable safety and efficacy profile relative to placebo. The data for cohort three stands out in particular, showing responses that came earlier and went deeper than those seen in cohorts one and two. Beyond that, the newest biomarker findings from the trial keep reinforcing the ITK inhibition mechanism of action, which includes the possible induction of anti-inflammatory T regulatory cells. I'll walk through the specifics of the data being shared at SID, plus give an overview of the trial as it continues and what we have planned for both the ongoing phase I trial and the phase II trial we intend to run in atopic dermatitis. On slide six, you can see how the phase I clinical trial was designed. To be eligible, patients must meet the Hanifin and Rajka criteria, have moderate to severe atopic dermatitis, and have not responded to at least one earlier systemic or topical therapy regimen. Four cohorts are enrolled one after another, and enrollment for the first three of them is now complete. Each cohort contains 16 subjects — four on placebo and 12 on active drug. This is a double-blind study. Neither the patient nor the physician knows the treatment assignment, and the placebo and active tablets cannot be told apart. Our company remains unblinded, so we can assess the data as the study moves forward. Our aim was to preserve the option to adjust or amend the trial based on data available as it progressed, given that this is a novel agent whose mechanism of action has not previously been studied in this indication. Patients take study drug or placebo across 28 days, after which they are followed for another 30 days off therapy, adding up to 58 days on study; we structured the study this way so we could evaluate safety and efficacy during treatment and also detect any possibility of effects that persist once the drug is stopped. Safety and efficacy serve as the trial's endpoints, measured through EASI, the Eczema Area and Severity Index scores, and IGA, the Investigator's Global Assessment. Every cohort looks at a different dosing regimen. The four cohorts are as follows: first, 100 mg oral twice a day, giving a total dose of 200 mg per day. Second, 200 mg oral once a day — a different schedule, but likewise a total dose of 200 mg per day. The third cohort, 200 mg oral twice a day, for a total dose of 400 mg per day. Fourth cohort, 400 mg oral once a day. These doses were chosen based on what we learned from T-cell lymphoma patients. We've demonstrated that at these doses, you get substantial or even full occupancy of the ITK target. In our phase III registration lymphoma trial that's currently running, the dose under evaluation is 200 mg given twice daily. On the next slide, you can see the characteristics for the 48 patients who were enrolled and treated across cohorts one, two, and three. We show the placebo and Soquelitinib arms, plus the pooled cohorts. A few characteristics deserve mention. In cohort three, mean baseline EASI scores came in around 27 to 28 for both the Soquelitinib and placebo arms — markedly above cohorts one and two, which fell in the 17 to 20 range; this tells us cohort three patients began with more severe disease. Along the same lines, cohort three also had a greater percentage of patients for whom prior systemic therapies had failed. In fact, disease in two treated patients proved refractory or resistant to DUPIXENT. Across all groups, there is a large proportion of African Americans. Patients in this population are reported to face a worse prognosis. Broadly speaking, Soquelitinib and placebo patients are quite well balanced when it comes to patient characteristics. The cohort three placebo patients are younger, though age is not a prognostic variable. Let's now turn to the efficacy results, presented in the table on slide eight. That table displays day 28 results for patients in the Soquelitinib and placebo groups. Cohorts one and two are pooled, given how similar both their characteristics and their results were. Results for the combined cohorts one and two appear on the left side, while the right side shows results for cohort three patients who have completed 28-day follow-up — eight on active drug and four on placebo. Another four patients in cohort three receiving active drug have finished day 15 follow-up but haven't yet reached the 28-day follow-up point; for cohorts one and two, the mean EASI score reduction in the placebo group is 30.6%, versus 54.6% for the Soquelitinib group, an absolute difference of 24.0%. In cohort three, the mean percent reduction in EASI score for the placebo group is 42.1%, compared with 71.1% for the Soquelitinib group, an absolute difference of 29.0%. Turning to EASI 50, we observe that patients on placebo and on Soquelitinib alike frequently reach EASI 50. Things look quite different for EASI 75, EASI 90, and IGA zero or one, the endpoints regarded as clinically meaningful. Not a single placebo patient reached EASI 75, EASI 90, or IGA zero or one; among Soquelitinib patients in cohorts one and two, 29% reached EASI 75 and 4% reached EASI 90, whereas in cohort three, 63% reached EASI 75 and 13% reached EASI 90. IGA zero or one was achieved by 21% of patients in the cohort one and two Soquelitinib groups, while in cohort three, 25% of the Soquelitinib group reached IGA zero or one. On the following slide, you can see how the patients given Soquelitinib responded over time in cohorts one, two, and three, along with the pooled placebo subjects drawn from all three of those cohorts. Placebo is depicted by the orange line. Cohorts one and two, shown as the blue and red lines, start to diverge from placebo by day 15 and continue to show greater separation by day 28. That gap holds through the 30-day period after treatment ends. The curves for cohorts one and two almost sit on top of one another, which tells us the twice-daily and once-daily schedules perform the same; it looks like QD dosing is feasible for this drug. Cohort three, the green line, separates from placebo sooner and more strongly by day eight, and EASI score improvement keeps building through days 15 and 28. Data for cohort three covers all 12 Soquelitinib-treated patients in that cohort through day 15, and then eight patients at day 28, since four patients have not yet hit their 28-day follow-up. Notably, those four patients in the Soquelitinib arm are showing day 15 results in line with the rest of the patients, so we would expect that pattern to carry through to day 28. Every placebo patient has made it to the day 28 follow-up.
Richard Miller
executiveI want to highlight that across every treatment group, the curves trend downward between day 15 and day 28, which hints that extending how long patients are treated might drive responses even deeper. Slide 10 presents the same analysis as the previous slide, except the data for cohorts one, two, and three are pooled together, represented by the blue line. These are the results covering all patients. By day 15, a gap from placebo emerges, and once day 28 arrives, the difference reaches statistical significance versus placebo, with a p equal to 0.03. The following slide lays out efficacy for every treatment cohort along with the pooled placebo groups. Not a single placebo recipient reached EASI 75 or an IGA score of zero or one. Meaningful differences emerge for the active groups relative to placebo, and cohort three looks like it outperforms the other cohorts. Results pooled across the Soquelitinib cohorts are statistically significantly superior to placebo. Let's now turn to safety. As this slide indicates, no notable safety concerns turned up with Soquelitinib, and nothing distinguished the treated groups from the placebo groups. Just one adverse event tied to treatment occurred in a patient on Soquelitinib: a grade one case of nausea. No laboratory abnormalities of clinical significance were observed. Cumulative experience with Soquelitinib now spans more than 100 patients who have T-cell lymphoma or atopic dermatitis, amounting to roughly 9,000 patient treatment days. Within our lymphoma study, certain patients have received uninterrupted daily dosing for as long as two years. Given these findings, we have modified the phase I trial protocol, as described on slide 13. At the bottom of that slide, in purple, you can see that the originally planned cohort four is being swapped for an extension cohort, which will assess an additional 24 patients at the 200 mg twice per day dose administered for eight weeks, followed by an extra 30-day follow-up off therapy. Drawing on our occupancy and pharmacokinetic studies, we concluded cohort four was unlikely to yield more useful information. By substituting a new cohort for that one, we anticipate no loss of time. Those 24 patients will be randomly assigned in a blinded manner, one to one against placebo, 12 on active drug and 12 on placebo. We think this amendment creates an opportunity to assess whether longer treatment duration can produce greater efficacy. We expect data from the extension cohort to become available in the fourth quarter of this year; that added experience ought to help us refine the design of our phase ii trial, which we are advancing concurrently and still expect to launch before this year ends. Phase II will probably test varying doses and treatment durations, among them once per day dosing of the drug; to wrap up, the trial results keep us encouraged, since they demonstrate a favorable safety and efficacy profile with a convenient oral tablet. The data's main takeaways are that across all 3 cohorts, a meaningful drop in EASI score appeared by day 28 of therapy, and the split from placebo was unambiguous. In cohort 3, where the dose was 200 mg given twice daily, responses came sooner and went deeper compared with cohorts 1 and 2. That lines up with what our pharmacokinetic analysis would predict. When cohorts 1 and 2 were compared on 200 mg once daily against 100 mg twice daily, activity looked the same, which points to QD dosing being feasible. After treatment ended, a benefit lasting 30 days held up in all 3 cohorts, possibly because of a rise in T reg cells. We didn't see any rebound events of the kind associated with JAK inhibitors. Looking at safety across all 3 cohorts, Soquelitinib comes across as very well tolerated. Given what the results show so far, we're bringing in a new extension cohort to test a longer treatment period of 56 days, or eight weeks. Taking a wider view, the safety, the mechanism of action, and other characteristics indicate Soquelitinib may become a significant new option for many immune diseases. Now a short business update covering the quarter. Enrollment keeps going in our registrational phase III study of soquelitinib among patients who have relapsed peripheral T-cell lymphoma, and we're pushing toward interim data in late 2026. In our phase II study of Soquelitinib for patients with ALPS, or autoimmune lymphoproliferative syndrome, the first patient has now been dosed. Based on how enrollment trends go, initial data from the phase two ALPS study might arrive in late 2025 or early 2026. To wrap up, these Soquelitinib findings in atopic dermatitis highlight even more its wide potential across a range of oncology and immune disease indications; that covers our clinical programs for PTCL, atopic dermatitis and ALPS, our planned study for solid tumors, and a lengthy list of immune diseases we could potentially target with Soquelitinib or our next generation ITK programs. We're very pleased about the early exercise of warrants announced today, bringing in an extra $31 million and letting us move Soquelitinib forward on multiple fronts, among them key data from the next 24 patients in the atopic dermatitis trial, which we expect during the fourth quarter of 2025. Our current cash carries us into late 2026. We're eager to share updates on our programs in the quarters ahead. At this point I'll hand the call to the operator for a question and answer period. Operator.
Aydin Huseynov
analystHello there, and good afternoon to all of you. Richard, nice work on those impressive results — congratulations. I've got a few things I'd like to ask; it appears that the EASI 75 figures from your cohort three at week four are better than what DUPIXENT shows at week 16. On top of that, it looks like the numbers you're seeing are moving nearer to JAK inhibitors rather than DUPIXENT. In your view, might Soquelitinib one day be prescribed before DUPIXENT and go head-to-head with JAK inhibitors? I'm just interested in what you think.
Richard Miller
executiveAyden, I appreciate you asking that. To start with, cohort three involves only a limited number of patients, so we should keep that somewhat in mind. Yes, in my view our four-week results stack up well against other treatments approved for atopic dermatitis. Given the safety profile and the ease of taking an oral tablet, I could see this becoming an earlier option within systemic therapy. There's still plenty more for us to do before we know precisely where it belongs, but in my opinion the effort put in here reveals a novel mechanism that might be usable early in treating atopic dermatitis.
Aydin Huseynov
analystThanks for that, I appreciate it. I've got another thing I want to ask about, which relates to the efficacy curves — and once more, when we consider JAK inhibitors, my understanding is that for JAKs it levels off around week 8. Given how soquelitinib works, where do you see this possibly leveling off? Would it be week 8, 12, or 16? Do you have any thinking on that?
Richard Miller
executiveYes. Well, what stands out to us is that between day 15 and day 28 the curves keep dropping on a fairly steep incline, and after that they go flat the moment you discontinue the drug. That raises the question — it really prompts the question — whether continuing treatment would produce deeper, improved responses. We intend to examine that under our amended protocol; we also have instances in our trial of patients who were responding and kept improving through day 28, among them several of the very sick ones. They were still getting better on day 28, at which point the protocol required us to stop the drug. It genuinely brings up the question, and their physicians raised it too: "Gee, why can't we continue this since they were improving on the therapy?"
Aydin Huseynov
analystThanks. Thanks. That's really useful. For the final question: between cohort two and cohort three, there's a notable rise in EASI efficacy. As you said, of course, cohort three's patients were even sicker. What accounts for that kind of steep increase in efficacy? Sure, these are small numbers, and so on, but I'm just interested in what you think about it.
Richard Miller
executiveWe're giving more drug. The amount of drug is twice as much. Compared with cohorts one and two, cohort three uses double the dose — the total daily dose. We've doubled the dose of drug. A very careful analysis we carried out using our lymphoma patients indicates that once you increase the dose to that level, you essentially get occupancy around the clock, 24 hours a day. That may matter. It makes a great deal of sense. After carefully reviewing many different dose levels in our lymphoma study, we ultimately landed at 200 BID. All of this makes complete sense. Look, even at the beginning, I recall around December, January, when this was being discussed, we consistently stated our expectation that the third cohort would do better. And it does. Whether 200 BID would be equivalent to perhaps 400 once a day remains an open question, I think. Eventually we have to test that; it's something we're considering as we design our phase II trial.
Aydin Huseynov
analystUnderstood. Many thanks, Richard. Once more, congratulations on such impressive data.
Graig Suvannavejh
analystWonderful. I appreciate you answering my questions. We'd also like to add our congratulations regarding the atopic dermatitis results. What I'd like to inquire about is the change made to the phase I trial along with the longer-duration cohort. The reasoning behind treating patients for a longer period makes complete sense to me. I believe I picked up on something — though I could be mistaken — that you may be thinking about including a QD dose there. Assuming that's accurate, and considering the remarks that the 400 QD dose might not be particularly differentiated, I'm curious what that possible QD dose would look like should you decide to evaluate it within the extended duration cohort. Thank you.
Richard Miller
executiveThe extended duration involves 24 patients — 12 on active treatment and 12 on placebo. A single dosing regimen, meaning one dose, will be examined: 200 mg BID. All right. Thanks. Thanks. That's what I brought up, yes. Yes. Yes.
Graig Suvannavejh
analystAll right. It really appears that, at least right now, 200 mg BID is the best dose across both oncology and, at a minimum, the atopic dermatitis indications.
Richard Miller
executiveThat is right.
Graig Suvannavejh
analystAll right. I appreciate that. Let me ask, focusing on the information you presented earlier today, when we examine cohort two, there was a discrepancy in what was observed regarding at least EASI 75, with the figures declining. My assumption is that this stems from the additional subjects you brought in. You didn't actually observe them reaching EASI 75. Now, considering the four remaining subjects who haven't been reported yet, since I believe their follow-up isn't complete, do you have any perspective on how much they might add to the efficacy results you're currently seeing? Thanks.
Richard Miller
executiveI'm not entirely clear on your point. You're saying the figures for the 200 QD are somewhat lower than what we presented in January. The extra subjects. Yes. Okay. To begin with, once again, these are small numbers, but a few of those subjects were EASI 72 and EASI 68. I mean, a portion of this is truly quite close. I believe there was genuinely no meaningful distinction. When you examine our cohort three, when you examine the EASI scores among the eight subjects at day 15 and the four who are also at day 15, they are remarkably similar. You can observe that, in fact, when you look at the standard error bars on the green, they are extremely narrow.
Graig Suvannavejh
analystAlright. Perhaps one final item, if I can slip it in. This ought to be a brief, simple thing to address. At what point do you anticipate disclosing the full cohort three results covering each of the 12 patients?
Richard Miller
executiveMy guess is we'd be able to put that out through a press release, likely within 1 or 2 months.
Graig Suvannavejh
analystAll right. Many thanks, and once more, well done on the data.
Lee Watzek
analystHello, congratulations on the data too. Perhaps a few questions from our side. First, regarding the placebo arm, if I examine the EASI change from baseline, it appears this arm likewise declined and didn't truly bounce back. So the question is whether this placebo response is normal relative to other AD trials, and did just a small number of patients produce this placebo response?
Richard Miller
executiveSome placebos do rebound and worsen; actually, looking at the standard error bars for the placebo, you'll notice they're fairly wide. A few patients did, in fact, get worse. Is that typical? Honestly, I believe our placebos acted much like the others. I mean, certain recent trials have shown even more, I suppose, greater improvement among placebo groups, yet that isn't what we observed. One thing we did — and I lacked the time to cover this during the presentation — was monitor the EASI scores. Looking at the graphs on slides nine and 10, from screening to baseline, that spans roughly 2 weeks; that's when the patient arrives and undergoes the required testing to confirm eligibility. EASI scores get measured at the start of that period and, naturally, prior to starting treatment. Notice how consistent they remain across all the groups. That reflects well on the physicians, our staff, and the training regarding EASI scores and how consistent they were. As soon as you take a pill, a placebo effect clearly appears, and a portion of those placebo patients improve. No, there's nothing odd about our placebos here. I think one point: our placebos, 0% of EASI 75s and 90s, which is far lower than what you'd observe in the DUPIXENT or JAK inhibitor trials, where you'd see 10%, 15%, 20% achieving EASI 75 or IGA zero one. Remember, those trials run longer. In them, you're in the study for 3 months, 6 months, or more. The longer you remain in a study, the greater the likelihood a placebo might improve and hit that threshold.
Lee Watzek
analystAlright, got it.
Richard Miller
executiveThat's clear, right? Yeah, I appreciate you clearing that up. I'm just wondering whether you're seeing a different kind of response between patients who've had systemic therapy before and those who haven't. It's too soon to say much about that, but in cohort three we had a pair of patients — one of them was totally refractory to DUPIXENT, with a baseline EASI sitting in the mid-40s. Alright, let me start with that one. That person had not gotten anywhere with DUPIXENT, no response whatsoever. A JAK inhibitor and methotrexate also produced nothing, and then this patient started our drug and got substantially better, kept improving across the study, though once again we had to halt at day 28. Naturally the physician wanted to keep going, but that wasn't possible. The other person had an EASI in the high 30s, had been on DUPIXENT for some time, had a response to it, then got worse again, was restarted on DUPIXENT, and showed no response, none at all, and then went on our drug and reached an EASI 90 — hit an EASI 90 with our drug. So that's an N of two. Whether it's responder versus non-responder, or refractory versus resistant versus no prior systemic therapy, I can't say. What that means prognostically, I don't know, since we have only a handful of such patients. My view would be that since our mechanism of action doesn't overlap with those agents, there's no reason I can see that someone with prior JAK or DUPIXENT exposure would differ from someone without. Everything here seems to line up quite consistently with what we've learned in the lab, what we've learned in animal models, and honestly, what we've learned from our lymphoma studies.
Lee Watzek
analystFantastic. Congratulations once more.
Jeff Jones
analystHello, everyone, and well done again on those truly remarkable results. Richard, you mentioned receptor occupancy a bit. In these patients up through cohort three, have you examined receptor occupancy at all, to determine whether there could be any variation between what you've observed in the T-cell lymphoma patients and the AD patients?
Richard Miller
executiveWe haven't examined that in these patients, since we've treated such a large number of lymphoma patients, and this comes down to chemistry, Jeff. When your concentration reaches a particular level, the receptor will be bound. This is a covalent drug. Incidentally, we already know that level. It's 300 ng per ml of drug.
Jeff Jones
analystAll right. When we examine these figures, it's clear the EASI 75 values declined a bit compared with what you first shared from a subset of the two-patient cohort. My recollection is that figure was roughly 57% EASI 75. That value looks fairly close to the 63% you're now citing for cohort three, where 8 of the 12 patients treated so far, in other words n equals 8, have responded. The drug is plainly quite active, so I suppose the question is this: with such limited patient numbers right now, what specifically makes you confident about the dose effect you're observing between cohort two and cohort three?
Richard Miller
executiveTo begin with, once more, take a look at the kinetic curve on nine. Check slide nine, and the kinetics of response. Not only do we see a deeper response in cohort three, it also comes earlier; we know receptor occupancy is greater, and the patients in cohort three were sicker. Considerably sicker patients, in fact. And again, when we review the day 15 data for cohort three, it's quite consistent; that's what gives us confidence. As for cohort two shifting, once more, the number is very small. EASI 75 matters; it is somewhat arbitrary. As I said before, a few of the follow-up or later patients had EASIs in the low 70s and just missed the threshold; that comes down to luck of the draw. The reality is that by 28 days, a substantial number are responding. Actually, I'd go further and say that in cohort three, even if the next group of patients failed to respond, you'd still have, what, a 50% EASI 75, and that's a pretty good result.
Jeff Jones
analystNo. Thanks for that, Richard. I believe the kinetics genuinely support that narrative, along with the reality that every patient has now passed day 15. I suppose one final question regarding the runway guidance you provided. Could you share which trials factor into that? Since you folks certainly have quite a bit going on at the moment.
Richard Miller
executiveI'll hand that over to Leiv. Leiv, would you mind?
Leiv Lea
executiveAbsolutely, that covers every one of the studies Richard described. First, the extension portion of our phase I AD study, then kicking off the phase II AD study, then carrying on with the phase III lymphoma study, and near the end of the year, launching a solid tumor study — a small phase I study; all of those studies are included.
Jeff Jones
analystExcellent, really appreciate it, everyone, and congratulations once more.
Richard Miller
executivePerhaps the operator could take another question if there's time?
Roger Song
analystThanks. And congratulations on the data too. Appreciate you taking my question. I'll keep it to two quick ones, maybe. First, I just want to make sure I understand: your phase one extension cohort is going to be 200 mg BID for eight weeks. You said something about phase two, that you're looking at QD as one of the cohorts. Would that be 400 mg, or less, or more? And if it is 400 mg, where's the ceiling on dose when it comes to safety? I have a quick follow-up. Thank you.
Richard Miller
executiveOkay. To start with, keep in mind that in lymphoma, we went as high as 600 mg BID, and we saw no DLTs, and we never reached the maximally tolerated dose. Roger, the phase two trial hasn't been finalized by us yet. I'm somewhat reluctant to tell you precisely what that design looks like. What it will include is a minimum of two active dose groups. One that you want lower. Hopefully that one gives you a lower response. One that is your real dose. And then, naturally, there will be placebo. 200 mg BID is definitely going to be among the active doses. My thinking is that we'd either examine 200 QD, which might be one dose level, or possibly the 400 once a day. Okay. That hasn't been finalized by us yet. Part of why we're doing more patients — I mean, part of our goal is to confirm this 200 BID, to get additional measurements, to look at additional things. I should also point out, I didn't put this in the presentation, but if you check our poster and the presentation that Dr. Chu will give on Saturday, there are changes showing up in the cytokines and in the Treg cells, and cohort three is superior. The changes — let me put it this way — the cohort three changes are more dramatic.
Roger Song
analystUnderstood. Yeah. All right, that's quite useful. Perhaps one final quick question. From what I gather, your cash runway stretches across the entirety of phase II and then every one of the remaining indications. I'm just wondering what your thinking is regarding partnership. Might you pursue that conversation even ahead of phase II? Thanks.
Richard Miller
executiveNo. On our own, we intend to charge full speed ahead. That said, we do understand that creating treatments for a variety of autoimmune diseases is challenging or intricate. With multiple companies, we are currently in talks. Meanwhile, we will keep pressing onward; thanks to the additional cash that came in yesterday, we're able to get through our extension, which in my view will be a highly significant milestone, enter phase II, and keep advancing. No partners are required for us to proceed.
Roger Song
analystGreat. Thank you. Thank you, Rich.
Richard Miller
executiveAll right.
Richard Miller
executiveI believe there's another question in the queue? All right. Let's take one more. Is everyone?
Sean Lee
analystHi there. Good afternoon, everyone. Congratulations on those thrilling results, and I appreciate you fielding my question. I've only got one. Given that we're seeing side effects from this drug that are nearly absent, how do you view possible combos, whether for AD or for other indications? Thank you.
Richard Miller
executiveA great many folks keep raising that topic. I'm grateful you brought it up. Since its mechanism doesn't overlap with that of other drugs, and given its safety profile, and since it's taken orally and is easy to administer, an opportunity exists to pair it with other agents. I mean, the list of agents is long. I mean, clearly, the IL-13, such as a DUPIXENT, JAK inhibitors wouldn't be an insane thought, though I'd be concerned about the toxicity of the JAK inhibitors, the anti-IL-13s. I believe there are plenty of opportunities there; as of now, we're going to keep charging forward with monotherapy.
Sean Lee
analystAlright, I appreciate it.
Richard Miller
executiveVery well. That wraps up our conference call, I believe. Many thanks to everyone for joining us. As we continue ahead, we're eager to share news about our programs. Thanks again.
Operator
operatorThank you, everyone, for participating.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Corvus Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Corvus Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Corvus Pharmaceuticals, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.